MedTrace Logo

A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

NCT00423644 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2013-11-14

No results posted yet for this study

Summary

The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma

Conditions

Interventions

DRUG

Darinaparson

420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months

Sponsors & Collaborators

  • Alaunos Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00423644 on ClinicalTrials.gov